Company Overview
Snapshot
Founded in May 2019, Fibplant operates with 1–10 employees, including founder Haim Eliyahu. The company has secured funding across two rounds, with one disclosed grant event in May 2019.
Business overview
Fibplant is a Health Tech & Life Sciences company focused on developing a genetically engineered fibrinogen. This advanced active composition, based on therapeutic proteins produced in transgenic plants, is designed for use as a biological glue within the existing pharmaceutical drug market. The company's core technology serves the surgery and emergency medicine sectors, operating within the broader biopharmaceutical and drug development industries, with a focus on North America, Europe, and Southeast Asia.
Log in to access full profile ›Company Intelligence Q&A
- What is Fibplant's primary product focus?
- Fibplant is developing a genetically engineered fibrinogen intended for use as a biological glue in the pharmaceutical drug market. This product is based on therapeutic proteins produced in transgenic plants.
- When was Fibplant founded?
- Fibplant was founded in May 2019.
- Which industries does Fibplant's technology serve?
- Fibplant's advanced active compositions are made for the surgery and emergency medicine industries, leveraging biotechnology and genetic engineering.
- What is the current product development stage for Fibplant?
- Fibplant's products are currently in the R&D stage, as of May 2024, focusing on developing a genetically engineered fibrinogen.
- What is Fibplant's business model?
- Fibplant operates on a B2B business model.